Business Wire

ContourGlobal Scales up U.S. Renewables Presence With Acquisition of 446 MWp Solar PV Portfolio From Qcells

24.1.2025 11:29:00 CET | Business Wire | Press release

Share

ContourGlobal has acquired from Qcells a portfolio of 446 MWp of solar PV projects in Colorado (WECC) and Virginia (PJM), secured with long-term high-value utility PPAsThe portfolio comprises two projects, one under construction and with near-term commercial operations, and another one in late development. Both projects have secured permits, grid connections, and procurement contracts.The projects will include solar modules manufactured at Qcells’ U.S.-based Dalton and Cartersville production facilities in Georgia. Qcells is also performing development, EPC, and O&M services as part of its total solutions provider capability.

ContourGlobal and Qcells have announced a strategic transaction for a U.S. solar PV portfolio located in Colorado and Virginia with an installed capacity of 446 MWp. This transaction expands ContourGlobal’s planned solar PV and BESS capacity in the United States to almost 1.5 GW, when combined with more than 1 GW of recently acquired projects in late development stage located in South Carolina and Arizona.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122055737/en/

Antonio Cammisecra, CEO ContourGlobal (Photo: Business Wire)

Mr. Antonio Cammisecra, CEO of ContourGlobal, commented, “This transaction allows us to maintain momentum in our U.S. renewable growth, nearing 1.2 GW of solar PV capacity complemented with additional 0.3 GW of BESS capacity, in construction or late development. It also meaningfully accelerates the start of our commercial operations to the first half of this year. We are proud of this milestone and delighted that our partnership with Qcells will also enable us to integrate their U.S.-produced solar technology into these acquired projects.”

This latest portfolio, acquired from Qcells, is composed of two solar PV plants totalling 446 MWp and extends ContourGlobal’s renewable footprint in WECC (Western Electricity Coordinating Council) and PJM (Pennsylvania-New Jersey–Maryland) interconnection markets, providing regional diversification. The Colorado assets include 324 MWp already in construction, while the Virgina-located project of 122 MWp is expected to start construction in 2026.

Mr. IP Kim, Qcells GES President, said, “We are proud to support ContourGlobal’s US expansion. This transaction showcases Qcells’ differentiated capabilities as a ‘total energy solutions provider’ to bring projects from development into operations. We are excited to explore other opportunities where Qcells’ full suite of capabilities can deliver value to partners like ContourGlobal.”

The projects are located in attractive markets with growing demand load, paired with retirements of thermal capacity and carbon emission reduction targets at policy and corporate levels which provides opportunities for renewables development.

In particular, the Colorado assets will provide electricity to Platte River Power Authority (Platte River), a community-owned public power generation and transmission utility, under a long-term power purchase agreement. The first phase of the project, currently under construction in Northern Colorado, is a 185 MWp plant with commercial operation start estimated for the first half of 2025, and benefitting from a 22-year PPA. The second phase will bring an additional 139 MWp of capacity by 2026.

The Virgina 122 MWp project, is expected to start construction in 2026 and enter commercial operation in 2027, benefitting from a 20-year PPA with an investment grade investor-owned utility.

The total annual estimated production of the plants is more than 845 GWh, sufficient to power about 80,000 American households every year.

The agreement provides that Qcells will be responsible for the construction of the projects, which will include solar panels produced by the company at their Dalton and Cartersville facilities in Georgia. Qcells has one of the largest solar panel manufacturing facilities in the western hemisphere and, since 2019, its U.S. manufacturing capacity sits at 5.1 GW, and is expected to reach up to 8.4 GW.

Following this strategic acquisition, ContourGlobal’s total U.S. hybrid renewable capacity would reach approximately 1.5 GW - including approximately 1.2 GW of solar PV and 0.3 GW of BESS in all stages of maturity, from late development to construction. Notably, ContourGlobal also operates a 1.3 GW thermal portfolio spanning four states in the U.S.

CRC-IB served as exclusive buy-side advisor to ContourGlobal and Marathon Capital acted as exclusive financial advisor to Qcells for the transaction.

About ContourGlobal - ContourGlobal, a KKR Company, is an established Independent Power Producer (IPP) developing, acquiring and operating electricity generation and storage assets worldwide. Following the recently announced transactions, the company elevated its installed capacity under management, in late development or construction to around 7.8 GW. The footprint of the company now extends to 20 countries across Europe, Africa, Asia, North and South America. With a current share of renewables capacity of almost 50%, including capacity under construction or development, the company has committed to speed up the decarbonization of its portfolio with a sustainable transition of its thermal fleet, the repowering of existing renewable assets and the organic development of new renewable projects. ContourGlobal has gross pipeline of about 4.5 GW of development projects and a track record of 20 years of experience in partnering with communities, institutions and customers that benefit from its power supply through long-term contracts or innovative PPAs, coupled with energy management solutions.

About Qcells -Qcells USA provides complete utility-scale turnkey solutions through the entire project lifecycle from modules, solar and energy storage project development, and Engineering Procurement and Construction (EPC) services to the US utility-scale market. With a track record that includes 8.4 GW of sustainably produced module manufacturing capabilities in Georgia and nearly 2 GW of developed, constructed, and operating projects, Qcells USA is a dependable partner throughout the entire project lifecycle. Qcells USA is a flagship company of Hanwha Group, a FORTUNE Global 500 firm and a Top 7 business enterprise in South Korea. For more information, visit www.QcellsUSA.com and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250122055737/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare

HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release

HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye